Press

GLPTrackr in the media

GLPTrackr is the UK's first AI-powered companion app built specifically for Mounjaro and Wegovy users. We combine medication tracking, AI meal planning, food scanning, side effect management, and personalised insights — all adapted to the GLP-1 injection cycle.

If you're a journalist, editor, blogger, broadcaster, or content creator covering GLP-1 medications, weight loss, digital health, health tech, AI, nutrition, or pharmacy — we'd love to hear from you.

Company overview

GLPTrackr is the #1 ranked GLP-1 companion app in the UK. Built with pharmacy expertise and powered by GLPIQ 3.0 — the only AI trained exclusively for GLP-1 weight loss — the app helps Mounjaro and Wegovy users track their medication, eat smarter, manage side effects, and see real progress.

The app was designed to solve a problem that every GLP-1 user faces: there is no single app built for their medication. Users are forced to juggle multiple apps — one for calorie counting, one for dose reminders, one for weight tracking, one for meal ideas — none of which understand the GLP-1 injection cycle, how appetite changes throughout the week, or how to adjust nutrition around side effects.

GLPTrackr replaces all of them with one purpose-built app that adapts to the user's medication, dose, cycle day, side effects, and goals.

The app launched in 2026 and is available on iOS and Android.

Key facts and figures

Product: The UK's first AI-powered companion app designed exclusively for GLP-1 weight loss.

Built with direct input from practising UK pharmacists who dispense GLP-1 medications daily.

10+ integrated features in a single app — replacing the need for multiple separate health and fitness apps.

Available on iOS and Android with a 7-day free trial.

Features: AI meal plans personalised to the user's injection cycle, calorie target, protein goal, and side effects.

AI food photo scanning — snap any meal and receive a full nutritional breakdown in seconds.

Barcode scanning for instant UK supermarket product lookup.

Medication Clock — a real-time visual display of estimated medication levels throughout the injection cycle.

Golden Dose Finder AI — analyses the user's full dose history to identify which dose delivered the best weight loss with the fewest side effects.

Daily Brief — a personalised morning summary with insights, warnings, and recommendations based on the user's data and cycle day.

Predictive side effects — GLPIQ learns the user's personal side effect patterns and warns them the morning before a rough day.

What If simulator — lets users explore how changing their dose, diet, or habits might affect their results.

Injection tracking with dose reminders, injection site rotation, pen tracking, and remaining shots counter.

60-second morning check-in — log weight, mood, energy, appetite, food noise, and symptoms in under a minute.

Hydration tracking with daily targets and smart nudges.

Exercise and step tracking with cycle-adaptive activity targets.

Sleep tracking with bedtime, wake time, duration, and quality scoring.

Full progress analytics — weight trajectory, weekly nutrition trends, medication response, protein adherence calendar, wellbeing scores, and mood trends.

Weekly transformation cards — shareable summary cards showing the user's progress each week.

Unlimited progress photos with ghost overlay comparison.

Doctor PDF export — a formatted health summary the user can share with their GP or prescriber.

Body measurement tracking — waist, hips, chest, arms, thighs.

Recipe library with 50+ high-protein, GLP-1 friendly recipes filtered by meal type, prep time, and dietary needs.

Shopping list generated automatically from the user's weekly meal plan.

Community — a moderated space where GLP-1 users share experiences, side effect tips, meal ideas, milestones, and support.

Technology: GLPIQ 3.0 is the proprietary AI engine powering every intelligent feature in GLPTrackr.

GLPIQ is not a general-purpose AI adapted for health. It was designed from the ground up for GLP-1 weight loss, trained to understand injection cycles, medication phases, appetite patterns, side effect timelines, and the unique nutritional needs of users on these medications.

GLPIQ powers cycle-adaptive meal planning, predictive side effects, Golden Dose analysis, daily briefs, food photo recognition, and personalised insights.

The AI gets smarter with use — the more a user tracks, the more personalised and accurate their insights become.

Market context: GLP-1 receptor agonists including Mounjaro (tirzepatide) and Wegovy (semaglutide) are among the fastest-growing prescription medications in the UK and globally.

An estimated 2% of the UK population currently uses GLP-1 medications for weight loss, a figure projected to grow significantly over the coming years.

The global GLP-1 market is projected to exceed $100 billion by 2030.

Despite this growth, the companion app ecosystem remains underdeveloped. Most GLP-1 users rely on generic fitness and diet apps that do not account for injection cycles, medication-specific side effects, or the unique nutritional challenges of rapid pharmaceutical weight loss.

GLPTrackr is positioned as the category-defining solution for this underserved market.

Story angles

We're happy to support journalists and content creators with any of the following angles. These are suggestions — if you have a different angle in mind, get in touch and we'll do our best to help.

The technology angle

How AI is being used to personalise the GLP-1 weight loss journey. What GLPIQ 3.0 does, how it learns from user data, and why general-purpose AI models aren't enough for medication-specific health apps. How food photo scanning works. How the Golden Dose Finder analyses dose history. How predictive side effects are generated. The technical decisions behind building an AI health app in 2026.

The patient experience angle

Why GLP-1 users are juggling five apps and how GLPTrackr solves the "one app" problem. What daily life looks like for someone on Mounjaro or Wegovy — the nausea days, the appetite changes, the protein struggle, the emotional journey — and how the app fits into their routine. How the morning check-in, daily brief, and meal plans create structure and consistency. What users say about the experience.

The pharmacy angle

How pharmacists are going beyond dispensing to support GLP-1 patients. The clinical thinking behind features like cycle-adaptive meal plans, protein targets during rapid weight loss, and predictive side effect management. Why pharmacy expertise matters in health app design. The gap between prescribing and ongoing patient support and how technology is closing it.

The nutrition angle

What GLP-1 users should eat and why it's different from standard diet advice. How reduced appetite changes nutritional needs and why protein, fibre, and meal timing matter more on these medications. How AI-generated meal plans adapt to nausea days, low-appetite phases, and returning hunger. The challenge of hitting 120g+ protein on a reduced appetite and how the app helps.

The side effects angle

The reality of GLP-1 side effects — nausea, constipation, fatigue, food noise changes, hair thinning, brain fog — and how they vary by dose and individual. How GLPTrackr tracks side effects over time and uses AI to predict them before they happen. Why side effect management is the most underserved aspect of the GLP-1 patient journey.

The mental health and wellbeing angle

The emotional side of rapid weight loss — body image shifts, identity changes, food noise disappearing, the psychological adjustment to eating less. How GLPTrackr's mood, energy, and wellbeing tracking captures the mental health dimension that clinical apps miss. The role of community support in maintaining motivation and mental resilience.

The digital health and startup angle

Building a health app in the UK in 2026. The technical decisions behind the product, the AI stack, and how a small team is competing in a fast-growing market. The challenges of handling special category health data under UK GDPR. The decision to build AI features in-house rather than relying on third-party health APIs. How pharmacy expertise shaped the product roadmap.

The market and industry angle

The rise of GLP-1 companion apps and the growing ecosystem around weight loss medications. How the UK market compares to the US. Where the category is heading. What patients actually want from digital support tools. How established players like Weight Watchers are pivoting toward GLP-1 and what that means for purpose-built apps like GLPTrackr.

The body positivity and ethical angle

How GLPTrackr approaches weight loss without shame. Why the app tracks wellbeing alongside weight. How the community guidelines prohibit body shaming and medical advice between users. The responsibility of building a weight loss product in 2026 and how GLPTrackr navigates that.

What we can provide to media

Interviews

Our team is available for interviews via email, phone, video call, or in person (UK-based). We can speak to the product, the technology, the clinical reasoning behind key features, the market opportunity, and the user experience. We're comfortable with live broadcast, pre-recorded segments, podcasts, panel discussions, and written Q&A formats.

Product demonstrations

We can provide a live walkthrough of the app for editorial teams, including step-by-step demonstrations of key features such as AI meal scanning, the Medication Clock, Golden Dose Finder, meal plan generation, and the community. We can screen-share via video call or provide a recorded demo for your team to review at their convenience.

Press access

Verified journalists, editors, and reviewers can request a complimentary press account with full access to all GLPTrackr Premium features for review and editorial purposes. Press accounts are valid for 30 days and can be extended on request. To request a press account, email us with your name, publication, and a link to your editorial profile or recent work.

Expert quotes and commentary

We're happy to provide expert quotes and commentary for articles, reports, or broadcasts covering GLP-1 medications, weight loss technology, AI in health, nutrition for GLP-1 users, digital health trends in the UK, health app regulation, or the companion app market. We can turn around written quotes within 24 hours for deadline-sensitive stories.

Data and insights

As our user base grows, we will share anonymised, aggregated insights on GLP-1 user behaviour, nutrition patterns, side effect trends, dose response data, engagement metrics, and other relevant data points. These insights will be made available through periodic reports and on request to verified media. Get in touch to discuss what is currently available.

Photography and visual assets

Our press kit includes high-resolution versions of the GLPTrackr logo (light, dark, and monochrome versions), GLPIQ 3.0 badge, app screenshots across key features, product mockups (iPhone and Android), lifestyle mockups, and brand colour and typography guidelines. All assets are available for editorial use and can be provided in PNG, SVG, and PDF formats. Custom assets can be produced on request for feature pieces or cover stories.

Case studies and user stories

With user consent, we can connect journalists with GLPTrackr users who are willing to share their personal GLP-1 journey and experience with the app. User stories are available for written interviews, video features, and podcast appearances. All user participation is voluntary and coordinated through our team to protect user privacy.

Brand guidelines for media

When referencing GLPTrackr in your coverage, please observe the following:

App name

The app name is GLPTrackr (capital G, L, P, T — lowercase r, a, c, k, r). It is one word with no spaces.

Correct: GLPTrackr Incorrect: GLP Trackr, Glptrackr, GLP-Trackr, GLP Tracker, Glp Trackr, glptrackr

GLPTrackr should be followed by the ™ symbol on first mention in any article or publication: GLPTrackr™. Subsequent mentions in the same article do not require the ™ symbol.

AI system name

GLPIQ 3.0 is the name of our proprietary AI system. It should always be written in capitals with the version number included: GLPIQ 3.0.

Correct: GLPIQ 3.0 Incorrect: GlpIQ, GLPIQ, Glpiq 3.0, GLP-IQ 3.0

Logo usage

Please do not alter, recolour, distort, rotate, crop, add effects to, or place the GLPTrackr logo on backgrounds that reduce its legibility. Minimum clear space and size requirements are included in the press kit. If in doubt, contact us and we'll provide a version that works for your layout.

Medical disclaimer

Please do not state or imply that GLPTrackr is a medical device, provides medical advice, diagnoses, or treatments, or is a substitute for professional healthcare. GLPTrackr is a wellness companion app. If your coverage references the app's AI features, please include a note that AI-generated content is for informational purposes only.

Screenshots and mockups

You are welcome to use official screenshots and mockups from our press kit in editorial coverage. If you wish to capture your own screenshots from a press account, please ensure they do not display any real user data, personal information, or community content from other users.

Recent coverage

We'll add links to press coverage here as it becomes available. If you've covered GLPTrackr and your article isn't listed, let us know at hello@glptrackr.com and we'll add it.

Frequently asked questions from media

What is GLPTrackr? GLPTrackr is the UK's first AI-powered companion app built specifically for users of GLP-1 weight loss medications including Mounjaro (tirzepatide) and Wegovy (semaglutide). It combines medication tracking, AI meal planning, food scanning, side effect management, and personalised insights in a single app designed around the injection cycle.

What is GLPIQ 3.0? GLPIQ 3.0 is the proprietary AI engine that powers every intelligent feature in GLPTrackr. It was built from the ground up for GLP-1 weight loss — not adapted from a general-purpose AI. It powers meal plans, predictive side effects, Golden Dose analysis, daily briefs, and food photo recognition.

Is GLPTrackr a medical device? No. GLPTrackr is a wellness companion app. It does not provide medical advice, diagnosis, or treatment. All AI-generated content is for informational purposes only. Users are always advised to consult their prescribing doctor or pharmacist.

Who built GLPTrackr? GLPTrackr was built with direct input from practising UK pharmacists who dispense GLP-1 medications daily. The product is designed with a pharmacy-first approach, informed by clinical understanding of dose titration, side effect patterns, nutritional needs during rapid weight loss, and the challenges of reduced appetite.

What medications does GLPTrackr support? GLPTrackr currently supports Mounjaro (tirzepatide) and Wegovy (semaglutide), including all dose levels for both medications. Additional GLP-1 medications will be added in the future.

How much does GLPTrackr cost? GLPTrackr offers a single Premium plan at £9.99/month with a 7-day free trial. A founding member offer of £4.99/month (50% off, lifetime price lock) is available to the first 1,000 subscribers.

Where is GLPTrackr available? GLPTrackr is available in the UK on iOS and Android.

How does GLPTrackr handle user data? GLPTrackr processes special category health data under UK GDPR with explicit user consent. All data is encrypted in transit and at rest. No personal identifiers are sent to AI processing providers. User data is never sold to third parties. Full details are available in our Privacy Policy and Data Protection page.

Can I review the app? Yes. Verified journalists and reviewers can request a complimentary 30-day press account with full Premium access. Email us with your name, publication, and editorial profile.

Can I interview the GLPTrackr team? Yes. We're available for interviews across all formats — written, phone, video, podcast, and in-person (UK). We can turn around written quotes within 24 hours.

Media enquiries

For all press and media enquiries, contact us at:

Email: hello@glptrackr.com

Subject line: Press Enquiry — [Publication/Outlet Name]

We aim to respond to all media enquiries within 24 hours. For urgent or deadline-sensitive stories, please mark your email as urgent and include your deadline in the subject line.

Your cart is empty